Cargando…

Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide. Local ablation, such as radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation, etc., are well established in elimination and control of HCC. However, high recurrence rate after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shuling, Zeng, Xuezhen, Su, Tianhong, Xiao, Han, Lin, Manxia, Peng, Zhenwei, Peng, Sui, Kuang, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726793/ https://www.ncbi.nlm.nih.gov/pubmed/36505437 http://dx.doi.org/10.3389/fimmu.2022.1033000

Ejemplares similares

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis
por: Shen, Shunli, et al.
Publicado: (2018)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
por: Bao, Lei, et al.
Publicado: (2023)

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
por: Datta, Jashodeep, et al.
Publicado: (2015)

Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
por: Li, Jiarui, et al.
Publicado: (2023)

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

Is there a rationale for supplementing with vitamin D patients under treatment with allergen immunotherapy?
por: Di Gioacchino, Mario, et al.
Publicado: (2023)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
por: Chen, Shuling, et al.
Publicado: (2019)

Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
por: Xie, Hongyu, et al.
Publicado: (2021)

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
por: Wanderley, Carlos Wagner S., et al.
Publicado: (2022)

Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy
por: Wang, Yanan, et al.
Publicado: (2022)

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
por: Tai, David, et al.
Publicado: (2019)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
por: Seliger, Barbara, et al.
Publicado: (2022)

Immunotherapy in endometrial cancer: rationale, practice and perspectives
por: Cao, Wenyu, et al.
Publicado: (2021)

Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012)

T-lymphocytes from focused ultrasound ablation subsequently mediate cellular antitumor immunity after adoptive cell transfer immunotherapy
por: Ran, Li-Feng, et al.
Publicado: (2023)

Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
por: Hong, Ting, et al.
Publicado: (2022)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
por: Gao, Xidan, et al.
Publicado: (2021)

Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma
por: Yu, Xue, et al.
Publicado: (2022)

Localized Interleukin-12 for Cancer Immunotherapy
por: Nguyen, Khue G., et al.
Publicado: (2020)

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy
por: Yin, Li, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy
por: Liu, Jinping, et al.
Publicado: (2023)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Prognostic stratification based on m(5)C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis
por: Ding, Ziniu, et al.
Publicado: (2021)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

The Future of Immunotherapy: A 20-Year Perspective
por: Wraith, David C.
Publicado: (2017)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Cancer immunotherapy strategies that target the cGAS-STING pathway
por: Tian, Zhuoying, et al.
Publicado: (2022)

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors
por: Ji, Xiaoqin, et al.
Publicado: (2023)

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
por: Shou, Jiawei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5h2jkhapce7imla7dgc519eaf3